Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

REG - JPMorgan Sec.Plc Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Takeda Pharma Co Ltd amendment





 




RNS Number : 4761Z
JPMorgan Securities Plc
31 August 2018
 

AMENDMENT

INCREASED EQUITY SALES BY 400 TO 59,550

ADDED EQUITY SWAP PURCHASES OF 109,316

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Takeda Pharmaceutical Company Limited

(c) Name of the party to the offer with which exempt principal trader is connected:

Joint Financial Adviser to Takeda Pharmaceutical Company Limited

(d) Date dealing undertaken:

28 August 2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

     If it is a cash offer or possible cash offer, state "N/A"

Yes, Shire plc

 

 

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

(JPY)

Lowest price per unit paid/received

(JPY)

Common Stock

Purchases

 

Sales

59,350

 

59,550

4,700.0000

 

4,700.0000

4,651.0000

 

4,651.0000

 

(b)        Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

Common Stock

Equity Swaps

Long

 

 

 

 

 

 

 

 

 

 

 

 

 

Short

46,402

800

200

3,900

300

100

3,400

600

125,828

700

100

100

7,600

 

46,402

300

8,100

16,300

300

100

20,400

600

200

14

200

100

26,200

300

7,600

41.8711 USD

4,653.9000 JPY

4,655.0000 JPY

4,655.8462 JPY

4,657.8675 JPY

4,658.0000 JPY

4,659.2353 JPY

4,660.0000 JPY

4,660.1456 JPY

4,668.1718 JPY

4,678.0000 JPY

4,680.0000 JPY

4,684.9708 JPY

 

4,600.2193 JPY

4,656.6667 JPY

4,657.4258 JPY

4,657.6074 JPY

4,657.8667 JPY

4,658.3700 JPY

4,659.2108 JPY

4,660.0000 JPY

4,666.8967 JPY

4,667.1463 JPY

4,668.9003 JPY

4,669.0000 JPY

4,679.2595 JPY

4,680.0000 JPY

4,684.9707 JPY

 

(c)        Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

 

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 









 

(ii)        Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 





 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)


 

 



 

3.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

31 August 2018

Contact name:

Alwyn Basch

Telephone number:

020 7742 7407

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERBLGDIGBXBGIB

Recent news on Takeda Pharmaceutical Co

See all news